These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36527382)

  • 1. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study.
    Cai L; Tao T; Li H; Zhang Z; Zhang L; Li X
    J Glob Health; 2022 Dec; 12():11016. PubMed ID: 36527382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis.
    Zhang L; Wang X; Yao H; Ding B; Gao X; Li X
    Int J Equity Health; 2024 Jun; 23(1):116. PubMed ID: 38840134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Evidence of the Impact of the National Drug Price Negotiation Policy on the Availability, Utilization, and Cost of Anticancer Medicines in China: An Interrupted Time Series Study.
    Gao X; Yu M; Sun Y; Zhang T; Li X; Zhang L; Wang C
    Risk Manag Healthc Policy; 2024; 17():2201-2208. PubMed ID: 39309121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study.
    Zhu H; Zhu J; Zhou Y; Shan L; Li C; Cui Y; Kang Z; Jiao M; Liu H; Gao L; Wu Q; Hao Y
    Front Public Health; 2022; 10():921093. PubMed ID: 35844892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
    Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
    Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of medical insurance access negotiation on the utilization of innovative anticancer drugs in China: an interrupted time series analysis.
    Li C; Zhu J; Shan L; Zhou Y; Liu G; Zhu H; Wu Q; Cui Y; Kang Z
    BMC Health Serv Res; 2024 Jan; 24(1):90. PubMed ID: 38233857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
    Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
    Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data.
    Li BX; Wang YQ; Yi YY; Zhou N; Lv ZX; Ma R; Li X; Yuan N
    BMC Public Health; 2024 May; 24(1):1309. PubMed ID: 38745323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access to essential and innovative anti-cancer medicines: a longitudinal study in Nanjing, China.
    Cao Z; Wang L; Ma R; Hu Y; Bao B; Liu X; Li M; Wang X; Liu P; Li X
    BMC Health Serv Res; 2024 Jul; 24(1):802. PubMed ID: 38992687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis.
    Sun Y; Zhu Z; Zhang J; Han P; Qi Y; Wang X; Yang L
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data.
    Yang Y; Zhang Y; Wagner AK; Li H; Shi L; Guan X
    J Glob Health; 2023 Aug; 13():04083. PubMed ID: 37566690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis.
    Liu Y; Yi H; Fang K; Bao Y; Li X
    Front Public Health; 2022; 10():942638. PubMed ID: 35937254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysis.
    Qin Z; He M; Shen H; Liu S; Xu S; Chen L
    Front Public Health; 2024; 12():1381786. PubMed ID: 38903594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access to innovative anticancer medicines in China: a national survey on availability, price and affordability.
    Li W; Lu W; Chen H; Zhang C; Wang M; Zheng F; Wu HH; Wan GW; Yang Q; Ye L
    BMJ Open; 2024 Apr; 14(4):e077089. PubMed ID: 38670605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
    Zhang Y; Wei Y; Li H; Chen Y; Guo Y; Han S; Shi L; Guan X
    Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the National Health Insurance Coverage Policy on the Utilisation and Accessibility of Innovative Anti-cancer Medicines in China: An Interrupted Time-Series Study.
    Fang W; Xu X; Zhu Y; Dai H; Shang L; Li X
    Front Public Health; 2021; 9():714127. PubMed ID: 34422752
    [No Abstract]   [Full Text] [Related]  

  • 17. Access to anticancer medicines in public hospitals of Northwestern China.
    Ma Y; Peng J; Yao X; Feng L; Shi X; Jiang M
    Front Public Health; 2023; 11():1182617. PubMed ID: 37275477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
    Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
    BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Availability, Price and Affordability of Anticancer Medicines: Evidence from Two Cross-Sectional Surveys in the Jiangsu Province, China.
    Zhu Y; Wang Y; Sun X; Li X
    Int J Environ Res Public Health; 2019 Oct; 16(19):. PubMed ID: 31623326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accessibility of essential anticancer medicines for children in the Sichuan Province of China.
    Chen Z; Li S; Zou K; Li H; Zeng L; Lu X; Jia ZJ; Cheng G; Zhang L
    Front Public Health; 2022; 10():980969. PubMed ID: 36408013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.